<DOC>
	<DOCNO>NCT01797341</DOCNO>
	<brief_summary>The present study aim evaluate impact switch Prograf Advagraf renal function , trough tacrolimus level , drug-related adverse effect adherence stable recipient kidney-pancreas transplant . MPA pharmacokinetics also evaluate . The result study potential change current practice .</brief_summary>
	<brief_title>Prograf-Advagraf Cross Over Conversion Study</brief_title>
	<detailed_description>Tacrolimus ( Prograf © ) become part standard care patient receive solid organ transplant part immunosuppressive protocol use kidney-pancreas transplant recipient University Health Network ( UHN ) . Tacrolimus associate several toxicity , result , careful therapeutic drug monitoring tacrolimus key component post-transplant management . Trough serum concentration tacrolimus measure routinely use guide dose . Tacrolimus trough level know correlate total drug exposure . The Prograf formulation tacrolimus fairly short serum half-life must dose twice daily maintain therapeutic serum concentration . This result two high peak level day show correlate toxicity . Thus , avoidance high peak may desirable minimize tacrolimus toxicity . Advagraf new preparation tacrolimus formulate provide similar drug exposure tacrolimus daily dose regimen , avoids 2 daily high tacrolimus peak observe Prograf . In way , hop Advagraf may provide similar therapeutic efficacy Prograf few adverse effect . In addition , simpler dose regimen expect enhance patient adherence . Tacrolimus also show , along many drug , variable impact mycophenolate acid ( MPA ) pharmacokinetics . There currently data whether Advagraf impact MPA pharmacokinetics lesser degree Prograf . Eligible kidney-pancreas recipient recruit obtain informed consent , randomize continue current total daily Prograf dosage switch equivalent daily dose Advagraf . Patients continue randomize therapy 12 week cross opposite therapy another 12 week . Patients follow maintained medication designate week 24 . Bloodwork result , adherence AEs ( adverse event ) assess .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>recipient kidney pancreas transplant age 18 year old 12 month since time transplant stable allograft function ( creatinine &lt; 180 µmol/l eGFR &gt; 40 ml/min ) target tacrolimus trough level 510 ug/ml stable prior 3 mo . episode acute rejection within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Pancreas Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Prograf</keyword>
	<keyword>Drug Adherence</keyword>
</DOC>